Recombinant Antigens for 2015–2027 Influenza Vaccine Strains: Supporting Research Across Seasons
Influenza research evolves with every season. As circulating viruses change, researchers need access to relevant antigens to investigate antibody responses, develop assays, and compare findings across vaccine strains.
Sino Biological’s recombinant antigens for 2015–2027 influenza vaccine strains support this work through its ProVir® viral antigen collection. With hemagglutinin (HA), neuraminidase (NA), and nucleoprotein (NP) products representing recent and historical strains, the collection provides resources for both current research priorities and studies spanning multiple seasons.
Why Influenza Vaccine Strains Change
Influenza viruses continually evolve, making regular updates to vaccine composition necessary. Twice each year, the World Health Organization (WHO) reviews global surveillance data and recommends vaccine compositions for upcoming Northern and Southern Hemisphere influenza seasons. These recommendations help guide vaccine development and manufacturing.
The recommendations also provide an important reference for research reagent selection. Researchers evaluating antibody responses or developing antigen-detection assays need to consider both the strain and the antigen format relevant to their study.
Understanding the Latest Vaccine Recommendations
For the 2026–2027 Northern Hemisphere and 2027 Southern Hemisphere seasons, WHO recommends the same strain composition, with differences by vaccine production platform:
| Component | Egg-based vaccines | Cell culture-, recombinant protein-, or nucleic acid-based vaccines |
| A(H1N1)pdm09 | A/Missouri/11/2025-like virus | A/Missouri/11/2025-like virus |
| A(H3N2) | A/Darwin/1454/2025-like virus | A/Darwin/1415/2025-like virus |
| B/Victoria lineage | B/Tokyo/EIS13-175/2025-like virus | B/Pennsylvania/14/2025-like virus |
These recommendations distinguish the egg-based H3N2 component, A/Darwin/1454/2025, from A/Darwin/1415/2025 used for the other listed platforms. Current compositions contain two influenza A components and one B/Victoria component; historical B/Yamagata reagents should be considered separately from the current recommended composition.
Featured Recombinant Antigens for Current Strain Research
Sino Biological’s featured reagent selection includes HA trimer, NA, and NP products associated with the following strains*:
| Strain | HA trimer | NA | NP |
| A/Missouri/11/2025 (H1N1) | 41105-V08H | 41106-V08B | 41107-V08B |
| A/Darwin/1415/2025 (H3N2) | 41128-V08H | 41151-V08B | — |
| B/Tokyo/EIS13-175/2025 (B/Victoria lineage) | 41153-V08H | 41154-V08B | 41155-V08B |
| B/Pennsylvania/14/2025 (B/Victoria lineage) | 41152-V08H | 41154-V08B | 41155-V08B |
* This is a featured reagent table, rather than a complete list of WHO-recommended vaccine components.
Research Resources Across More Than a Decade of Strains
Research questions often extend beyond a single influenza season. Access to historical antigens allows researchers to design comparisons involving earlier vaccine strains alongside more recent ones.
The broader collection includes reagents for strains such as A/Victoria/4897/2022, A/Wisconsin/67/2022, A/Croatia/10136RV/2023, A/District of Columbia/27/2023, and B/Austria/1359417/2021, together with earlier strains dating back to the 2015–2016 season.
Depending on the strain, available formats include HA1, HA, HA trimers, biotinylated HA, HA-specific B-cell probes, NA, and NP. This variety helps researchers select reagents suited to their study design instead of relying on a single antigen format.
Supporting Antibody Analysis and Assay Development
Recombinant influenza antigens can support the analysis of vaccine-induced antibody responses. Sino Biological also offers monoclonal antibodies against influenza antigens to facilitate relevant assay development.
When selecting reagents, researchers should review the strain identity, protein format, labeling, and product-specific validation data. These details are especially important when comparing results across seasons or selecting complementary antigens and antibodies for an assay.
Explore the Influenza Antigen Collection
From recent vaccine strains to historical reference antigens, Sino Biological’s ProVir® collection provides a broad resource for influenza research.
Explore recombinant antigens for 2015–2027 influenza vaccine strains to view the full strain tables, available protein formats, and related research reagents.
